The interaction between early life complications and a polygenic risk score for schizophrenia is associated with brain activity during emotion processing in healthy participants.

early life complications emotion processing fMRI faces polygenic risk score schizophrenia

Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
02 Feb 2024
Historique:
medline: 2 2 2024
pubmed: 2 2 2024
entrez: 2 2 2024
Statut: aheadofprint

Résumé

Previous evidence suggests that early life complications (ELCs) interact with polygenic risk for schizophrenia (SCZ) in increasing risk for the disease. However, no studies have investigated this interaction on neurobiological phenotypes. Among those, anomalous emotion-related brain activity has been reported in SCZ, even if evidence of its link with SCZ-related genetic risk is not solid. Indeed, it is possible this relationship is influenced by non-genetic risk factors. Thus, this study investigated the interaction between SCZ-related polygenic risk and ELCs on emotion-related brain activity. 169 healthy participants (HP) in a discovery and 113 HP in a replication sample underwent functional magnetic resonance imaging (fMRI) during emotion processing, were categorized for history of ELCs and genome-wide genotyped. Polygenic risk scores (PRSs) were computed using SCZ-associated variants considering the most recent genome-wide association study. Furthermore, 75 patients with SCZ also underwent fMRI during emotion processing to verify consistency of their brain activity patterns with those associated with risk factors for SCZ in HP. Results in the discovery and replication samples indicated no effect of PRSs, but an interaction between PRS and ELCs in left ventrolateral prefrontal cortex (VLPFC), where the greater the activity, the greater PRS only in presence of ELCs. Moreover, SCZ had greater VLPFC response than HP. These results suggest that emotion-related VLPFC response lies in the path from genetic and non-genetic risk factors to the clinical presentation of SCZ, and may implicate an updated concept of intermediate phenotype considering early non-genetic factors of risk for SCZ.

Sections du résumé

BACKGROUND BACKGROUND
Previous evidence suggests that early life complications (ELCs) interact with polygenic risk for schizophrenia (SCZ) in increasing risk for the disease. However, no studies have investigated this interaction on neurobiological phenotypes. Among those, anomalous emotion-related brain activity has been reported in SCZ, even if evidence of its link with SCZ-related genetic risk is not solid. Indeed, it is possible this relationship is influenced by non-genetic risk factors. Thus, this study investigated the interaction between SCZ-related polygenic risk and ELCs on emotion-related brain activity.
METHODS METHODS
169 healthy participants (HP) in a discovery and 113 HP in a replication sample underwent functional magnetic resonance imaging (fMRI) during emotion processing, were categorized for history of ELCs and genome-wide genotyped. Polygenic risk scores (PRSs) were computed using SCZ-associated variants considering the most recent genome-wide association study. Furthermore, 75 patients with SCZ also underwent fMRI during emotion processing to verify consistency of their brain activity patterns with those associated with risk factors for SCZ in HP.
RESULTS RESULTS
Results in the discovery and replication samples indicated no effect of PRSs, but an interaction between PRS and ELCs in left ventrolateral prefrontal cortex (VLPFC), where the greater the activity, the greater PRS only in presence of ELCs. Moreover, SCZ had greater VLPFC response than HP.
CONCLUSIONS CONCLUSIONS
These results suggest that emotion-related VLPFC response lies in the path from genetic and non-genetic risk factors to the clinical presentation of SCZ, and may implicate an updated concept of intermediate phenotype considering early non-genetic factors of risk for SCZ.

Identifiants

pubmed: 38305128
doi: 10.1017/S0033291724000011
pii: S0033291724000011
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-10

Auteurs

Veronica Debora Toro (VD)

Psychiatric Neuroscience Group, Department of Translational Biomedicine and Neuroscience, University of Bari "Aldo Moro", Bari, Italy.
Department of Humanities, University of Foggia, Foggia, Italy.

Linda A Antonucci (LA)

Psychiatric Neuroscience Group, Department of Translational Biomedicine and Neuroscience, University of Bari "Aldo Moro", Bari, Italy.

Tiziana Quarto (T)

Department of Humanities, University of Foggia, Foggia, Italy.

Roberta Passiatore (R)

Psychiatric Neuroscience Group, Department of Translational Biomedicine and Neuroscience, University of Bari "Aldo Moro", Bari, Italy.

Leonardo Fazio (L)

Psychiatric Neuroscience Group, Department of Translational Biomedicine and Neuroscience, University of Bari "Aldo Moro", Bari, Italy.
Department of Medicine and Surgery, Libera Università Mediterranea "Giuseppe Degennaro", Bari, Italy.

Gianluca Ursini (G)

Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD, USA.
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA.

Qiang Chen (Q)

Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD, USA.

Rita Masellis (R)

Psychiatric Neuroscience Group, Department of Translational Biomedicine and Neuroscience, University of Bari "Aldo Moro", Bari, Italy.
U.O.C. Psichiatria Universitaria, Azìenda Ospedaliero-Universitaria Consorziale Policlinico, Bari, Italy.

Silvia Torretta (S)

Psychiatric Neuroscience Group, Department of Translational Biomedicine and Neuroscience, University of Bari "Aldo Moro", Bari, Italy.

Leonardo Sportelli (L)

Psychiatric Neuroscience Group, Department of Translational Biomedicine and Neuroscience, University of Bari "Aldo Moro", Bari, Italy.

Gianluca Christos Kikidis (GC)

Psychiatric Neuroscience Group, Department of Translational Biomedicine and Neuroscience, University of Bari "Aldo Moro", Bari, Italy.

Francesco Massari (F)

Psychiatric Neuroscience Group, Department of Translational Biomedicine and Neuroscience, University of Bari "Aldo Moro", Bari, Italy.

Enrico D'Ambrosio (E)

Psychiatric Neuroscience Group, Department of Translational Biomedicine and Neuroscience, University of Bari "Aldo Moro", Bari, Italy.
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8AF, UK.

Antonio Rampino (A)

Psychiatric Neuroscience Group, Department of Translational Biomedicine and Neuroscience, University of Bari "Aldo Moro", Bari, Italy.
U.O.C. Psichiatria Universitaria, Azìenda Ospedaliero-Universitaria Consorziale Policlinico, Bari, Italy.

Giulio Pergola (G)

Psychiatric Neuroscience Group, Department of Translational Biomedicine and Neuroscience, University of Bari "Aldo Moro", Bari, Italy.
Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD, USA.

Daniel R Weinberger (DR)

Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD, USA.

Alessandro Bertolino (A)

Psychiatric Neuroscience Group, Department of Translational Biomedicine and Neuroscience, University of Bari "Aldo Moro", Bari, Italy.
U.O.C. Psichiatria Universitaria, Azìenda Ospedaliero-Universitaria Consorziale Policlinico, Bari, Italy.

Giuseppe Blasi (G)

Psychiatric Neuroscience Group, Department of Translational Biomedicine and Neuroscience, University of Bari "Aldo Moro", Bari, Italy.
U.O.C. Psichiatria Universitaria, Azìenda Ospedaliero-Universitaria Consorziale Policlinico, Bari, Italy.

Classifications MeSH